Lectureship Awards

Dr. James D. Cox was a visionary radiation oncologist whose leadership at MD Anderson Cancer Center and within the Radiation Therapy Oncology Group (RTOG)—a pioneering NCI-supported cooperative group—helped define contemporary standards of thoracic radiation therapy. He advanced multidisciplinary trial design, integrating surgery, chemotherapy, and radiotherapy, and championed innovations such as conformal and proton therapy as well as translational research in radiation biology. His mentorship and global collaborations inspired generations of clinicians and scientists to pursue excellence in evidence-based care. The IASLC James D. Cox Lectureship Award for Radiation Oncology honors this enduring legacy by recognizing radiation oncologists whose innovation, scholarship, and international engagement reflect Dr. Cox’s profound influence. The award underscores the indispensable role of radiation oncology in IASLC’s mission to improve outcomes for patients with lung and thoracic cancers worldwide.

Dr. Heine H. Hansen was a Danish medical oncologist and one of the formative figures in the IASLC, helping organize the society from its earliest years and later serving as its Executive Director from 1994, during a period of major growth. He became internationally known for his work in small cell lung cancer (SCLC), where he led and promoted trials that established chemotherapy backbones (notably etoposide-based regimens), emphasized proper staging before therapy, and pushed to spread best-practice lung cancer care across borders. Because SCLC has lagged behind NSCLC in therapeutic progress, IASLC created the Heine H. Hansen Lectureship Award for Small Cell Lung Cancer to spotlight clinicians and investigators who, like Hansen, make sustained, practice-changing contributions in this specific disease. The award, presented at WCLC, also honors his view that international collaboration is essential if SCLC outcomes are to improve. In recognizing today’s SCLC leaders with an award in Hansen’s name, IASLC links ongoing advances directly back to one of the people who built the organization and championed SCLC as a global priority.

Dr. Daniel C. Ihde was a highly respected thoracic medical oncologist whose career significantly shaped lung cancer therapy and the infrastructure of clinical oncology research in the United States. He served at the National Cancer Institute (NCI) for 21 years (1973–1994), including as Deputy Director from 1991 to 1994. During his NCI tenure he was one of the earliest investigators to show that combination chemotherapy improved survival in SCLC, and later that specific agents had activity in NSCLC. After leaving NCI he became Chief of the Division of Medical Oncology at Washington University School of Medicine in St. Louis and continued to influence lung cancer care and clinical research. The Daniel C. Ihde Lectureship Award for Medical Oncology recognizes medical oncologists who have made outstanding, internationally-relevant contributions in thoracic oncology — particularly in systemic therapy, trial leadership, translational clinical research, and patient-centered impact. By naming it after Dr. Ihde, IASLC honors the legacy of a clinician-scientist who combined a deep understanding of lung cancer biology, clinical trial design, and institutional leadership — an example that today’s recipients are encouraged to follow.

Dr. Tsuguo Naruke was a pioneering Japanese thoracic surgeon at the National Cancer Center Hospital in Tokyo whose meticulous work on lung cancer surgery—especially complete mediastinal lymph node dissection—set international standards. He created the original pulmonary and mediastinal lymph node map in the late 1960s–1970s, and that “Naruke map” became one of the key foundations that later IASLC staging and lymph node maps had to reconcile, so his work is literally built into how IASLC classifies lung cancer today. He was also an early adopter of thoracoscopic approaches, showing that precise oncologic surgery could be combined with evolving minimally invasive techniques. The IASLC Tsuguo Naruke Lectureship Award for Surgery, presented at WCLC, therefore recognizes surgeons whose contributions advance the quality, precision, and global harmonization of lung cancer surgery in the same spirit. By honoring Naruke, IASLC underscores how careful anatomical study and standardized lymph node assessment remain essential to accurate staging and to improving surgical outcomes worldwide.

The IASLC Lectureship Award for Tobacco Control and Smoking Cessation recognizes individuals who have made exceptional contributions to reducing the global burden of lung cancer through tobacco control, prevention, and cessation initiatives. Established to highlight the critical intersection between public health and thoracic oncology, the award underscores IASLC’s long-standing commitment to addressing tobacco use as the leading cause of lung cancer worldwide. Recipients are typically researchers, clinicians, or advocates whose work has advanced evidence-based policy, behavioral interventions, or education that measurably decreases smoking prevalence or tobacco-related harm. The award also reflects IASLC’s belief that eliminating tobacco dependence is not only a public health goal but an essential component of comprehensive cancer care. By honoring achievements in tobacco control, IASLC reaffirms its role as a scientific and global leader in the fight to prevent lung cancer before it starts.